Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ACT200
MIFTS: 49

Acute Monoblastic Leukemia

Categories: Blood diseases, Cancer diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Acute Monoblastic Leukemia

About this section

MalaCards integrated aliases for Acute Monoblastic Leukemia:

Name: Acute Monoblastic Leukemia 54 60 6 74
Acute Monocytic Leukemia 54 60 74
Aml M5 54 60
M5b Acute Differentiated Monocytic Leukemia 74
Acute Monocytic/monoblastic Leukemia 74
Acute Myeloblastic Leukemia Type 5 54
Aml-M5 54

Characteristics:

Orphanet epidemiological data:

60
acute monoblastic leukemia
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Childhood;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34 35
Orphanet: 60  
Rare haematological diseases


External Ids:

ICD10 34 C93.0
MESH via Orphanet 46 D007948
ICD10 via Orphanet 35 C92.7
UMLS via Orphanet 75 C0023465 C0457334 C1318544
Orphanet 60 ORPHA514
Sources

Summaries for Acute Monoblastic Leukemia

About this section
NIH Rare Diseases : 54 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 514Disease definitionAcute monoblastic leukemia (AML-M5), is one of the most common subtypes of acute myeloid leukemia (AML; see this term) that is either comprised of more than 80% of monoblasts (AML-M5a) or 30-80% monoblasts with (pro)monocytic differentiation (AML-M5b). AML-M5 presents with asthenia, pallor, fever, and dizziness. Specific features of AML-M5 include hyperleukocytosis, propensity for extramedullary infiltrates, coagulation abnormalities including disseminated intravascular coagulation and neurological disorders. Leukemia cutis and gingival infiltration can also be seen. A characteristic translocation observed in AML-M5 is t(9;11).Visit the Orphanet disease page for more resources.

MalaCards based summary : Acute Monoblastic Leukemia, also known as acute monocytic leukemia, is related to monocytic leukemia and thrombocytosis. An important gene associated with Acute Monoblastic Leukemia is LPP (LIM Domain Containing Preferred Translocation Partner In Lipoma), and among its related pathways/superpathways are Pathways in cancer and JAK-STAT signaling pathway (KEGG). The drugs Sargramostim and Mesna have been mentioned in the context of this disorder. Affiliated tissues include myeloid, monocytes and bone.

Sources

Related Diseases for Acute Monoblastic Leukemia

About this section

Diseases related to Acute Monoblastic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 162)
# Related Disease Score Top Affiliating Genes
1 monocytic leukemia 32.4 CSF2 CXCL8 IL6 KMT2A
2 thrombocytosis 29.8 CSF2 EPO IL6
3 myeloma, multiple 29.7 CD44 CSF2 CXCL8 EPO IL6
4 adult acute monocytic leukemia 12.8
5 leukemia, acute monocytic 11.4
6 leukemia 11.1
7 sarcoma 10.5
8 myeloid sarcoma 10.4
9 engraftment syndrome 10.3 CSF2 CXCL8
10 felty syndrome 10.3 CSF2 CXCL8
11 vibrio vulnificus infection 10.3 EPO IL6
12 natural killer cell leukemia 10.3 EPO IL7
13 cyclic neutropenia 10.3 CSF2 CXCL8
14 recurrent corneal erosion 10.3 CXCL8 IL6
15 bagassosis 10.3 CXCL8 IL6
16 arteriovenous fistula 10.2 EPO IL6
17 acute transverse myelitis 10.2 CXCL8 IL6
18 transverse myelitis 10.2 CXCL8 IL6
19 streptococcal toxic-shock syndrome 10.2 CXCL8 IL6
20 denture stomatitis 10.2 CXCL8 IL6
21 lymphoma 10.2
22 lymphocytic leukemia 10.2
23 disseminated intravascular coagulation 10.2
24 funisitis 10.2 CXCL8 IL6
25 poems syndrome 10.2 EPO IL6
26 louse-borne relapsing fever 10.2 CXCL8 IL6
27 neutrophilia, hereditary 10.2 CSF2 IL6
28 aseptic meningitis 10.2 CD44 CXCL8
29 endometrial disease 10.2 CXCL8 IL6
30 anemia of prematurity 10.2 CSF2 EPO
31 vaginal disease 10.2 CXCL8 IL6
32 vaginitis 10.2 CXCL8 IL6
33 pyelitis 10.2 CXCL8 IL6
34 necrotizing fasciitis 10.2 CXCL8 IL6
35 b-cell growth factor 10.2 IL6 IL7
36 viral meningitis 10.2 CXCL8 IL6
37 radiculopathy 10.2 CXCL8 IL6
38 cowpox 10.2 CXCL8 IL6
39 ascaris lumbricoides infection 10.2 IL6 IL7
40 bacteriuria 10.2 CXCL8 IL6
41 leukemia, acute myeloid 10.1
42 leukemia, acute lymphoblastic 10.1
43 myelodysplastic syndrome 10.1
44 polyneuropathy 10.1
45 myeloid leukemia 10.1
46 xp22.3 microdeletion syndrome 10.1
47 childhood acute myeloid leukemia 10.1
48 reproductive system disease 10.1 CD44 CXCL8 IL6
49 gastrointestinal system disease 10.1 CD44 CXCL8 IL6
50 histiocytosis 10.1

Graphical network of the top 20 diseases related to Acute Monoblastic Leukemia:



Diseases related to Acute Monoblastic Leukemia
Sources

Symptoms & Phenotypes for Acute Monoblastic Leukemia

About this section
Sources

Drugs & Therapeutics for Acute Monoblastic Leukemia

About this section

Drugs for Acute Monoblastic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 219)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sargramostim Approved, Investigational Phase 3,Phase 2,Phase 1 123774-72-1, 83869-56-1
2
Mesna Approved, Investigational Phase 3 3375-50-6 598
3
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
4
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
5
Cytarabine Approved, Experimental, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4, 65-46-3 6253
6
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
7
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
8
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
9
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
10
Idarubicin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
11
Aldesleukin Approved Phase 3,Phase 1,Phase 2 110942-02-4, 85898-30-2
12
Thioguanine Approved Phase 3,Phase 1 154-42-7 2723601
13
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
14
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
15
Clofarabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 123318-82-1 119182
16
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
17
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
18
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
19
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
20
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
21
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
22
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 1 1177-87-3
23
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
24
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 143 6006
25
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
26
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
27
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 320-67-2 9444
28
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1 148-82-3 460612 4053
29
Carmustine Approved, Investigational Phase 3 154-93-8 2578
30
Hydroxyurea Approved Phase 3 127-07-1 3657
31
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
32
midostaurin Approved, Investigational Phase 3 120685-11-2 9829523 104937
33
Histamine Approved, Investigational Phase 3 51-45-6 774
34
Cyproheptadine Approved Phase 3 129-03-3 2913
35
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 444795 5538
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
37 Lintuzumab Investigational Phase 3,Phase 2 166089-32-3
38
tipifarnib Investigational Phase 2, Phase 3,Phase 3,Phase 1 192185-72-1 159324
39 Staurosporine Experimental Phase 3,Phase 1 62996-74-1
40 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Vaccines Phase 3,Phase 1
42 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Etoposide phosphate Phase 3,Phase 2,Phase 1
44 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Alkylating Agents Phase 3,Phase 2,Phase 1
48 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 189)
# Name Status NCT ID Phase Drugs
1 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
2 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
3 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
4 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
5 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
6 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
7 Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Completed NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
8 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
9 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
10 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
11 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
12 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
13 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
14 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
15 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
16 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
17 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
18 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
19 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3 cytarabine;laromustine
20 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
21 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
22 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
23 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
24 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
25 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT00093470 Phase 3 Tipifarnib
26 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
27 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
28 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
29 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
30 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Unknown status NCT02038153 Phase 1, Phase 2 Lenalidomide
31 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
32 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
33 Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
34 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
35 Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00006084 Phase 2
36 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
37 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
38 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
39 Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
40 Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Completed NCT01870596 Phase 2 Cytarabine;CHK1 Inhibitor SCH 900776
41 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT01361464 Phase 2 Tipifarnib
42 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine
43 Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT01349972 Phase 2 alvocidib;daunorubicin hydrochloride;mitoxantrone hydrochloride;cytarabine
44 AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT01253447 Phase 2 Akt inhibitor MK2206
45 Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy Completed NCT01235572 Phase 2
46 Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Completed NCT00895934 Phase 1, Phase 2 vorinostat;gemtuzumab ozogamicin;azacitidine
47 Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00634244 Phase 2 alvocidib;mitoxantrone hydrochloride;carboplatin;cytarabine;sirolimus;etoposide;topotecan hydrochloride
48 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00795002 Phase 2 alvocidib;mitoxantrone hydrochloride;cytarabine
49 Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00742625 Phase 1, Phase 2 daunorubicin hydrochloride;cytarabine;bortezomib
50 S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00093418 Phase 2 tipifarnib

Search NIH Clinical Center for Acute Monoblastic Leukemia

Sources

Genetic Tests for Acute Monoblastic Leukemia

About this section
Sources

Anatomical Context for Acute Monoblastic Leukemia

About this section

MalaCards organs/tissues related to Acute Monoblastic Leukemia:

42
Myeloid, Monocytes, Bone, Bone Marrow, B Cells, T Cells, Lung
Sources

Publications for Acute Monoblastic Leukemia

About this section

Articles related to Acute Monoblastic Leukemia:

(show top 50) (show all 406)
# Title Authors Year
1
Tetrasomy 8 Associated with a Poor Prognosis in Acute Monoblastic Leukemia: A Case Report. ( 31016095 )
2019
2
Cytogenetics and associated mutation profile in patients with acute monocytic leukemia. ( 31099482 )
2019
3
Analysis of Comparative Proteomic and Potent Targets of Peniciketal A in Human Acute Monocytic Leukemia. ( 30747080 )
2019
4
Differential Immunomodulatory Effect of Graphene Oxide and Vanillin-Functionalized Graphene Oxide Nanoparticles in Human Acute Monocytic Leukemia Cell Line (THP-1). ( 30634552 )
2019
5
Clonal dynamics in a case of acute monoblastic leukemia that later developed myeloproliferative neoplasm. ( 29417354 )
2018
6
Rare Coexistence of Acute Monoblastic Leukemia with Chronic Lymphocytic Leukemia. ( 30524762 )
2018
7
Morphologic and immunophenotypic features of a case of acute monoblastic leukemia with unusual positivity for Glycophorin-A. ( 30631409 )
2018
8
Atypical Acute Monocytic Leukemia: a Lymphoma Presentation and Association with Complex Karyotype. ( 30610055 )
2018
9
Induction of apoptosis in human acute monocytic leukemia (THP-1) cells with NaF and the related mechanisms. ( 30610810 )
2018
10
Anti-Cancerous Effect of Inonotus taiwanensis Polysaccharide Extract on Human Acute Monocytic Leukemia Cells through ROS-Independent Intrinsic Mitochondrial Pathway. ( 29382173 )
2018
11
Dihydroartemisinin-induced apoptosis in human acute monocytic leukemia cells. ( 29435054 )
2018
12
Acute monocytic leukemia diagnosed by flow cytometry includes acute myeloid leukemias with weakly or faintly positive non-specific esterase staining. ( 29721252 )
2018
13
Trisomy 6 as the sole stemline abnormality in a patient with acute monocytic leukemia: a case report. ( 29755835 )
2018
14
Haemophagocytic lymphohistiocytosis occurred during induction chemotherapy in an acute monocytic leukemia patient with FLT3-ITD and DNMT3A mutations. ( 29843647 )
2018
15
Enhanced Response of Acute Monocytic Leukemia Cells to Low-dose Cytarabine by 1,25-dihydroxyvitamin D3. ( 30074149 )
2018
16
Acute Monoblastic Leukemia Presenting with Multiple Granulocytic Sarcoma Nodules. ( 27094724 )
2017
17
Erythrophagocytosis by blasts in a case of de novo acute monoblastic leukemia with rare but characteristic t(8;16). ( 28272065 )
2017
18
Acute monoblastic leukemia presenting with striking periorbital and periauricular infiltration. ( 28642361 )
2017
19
Central hypothyroidism in a pediatric case of primary acute monoblastic leukemia with central nervous system infiltration: A case report. ( 28658145 )
2017
20
mRNA expression profiling of histone modifying enzymes in pediatric acute monoblastic leukemia. ( 29442054 )
2017
21
Generation of a MLL-AF9-specific stem cell model of acute monocytic leukemia. ( 27185517 )
2017
22
Bone Marrow Adipocytes Facilitate Fatty Acid Oxidation Activating AMPK and a Transcriptional Network Supporting Survival of Acute Monocytic Leukemia Cells. ( 28108519 )
2017
23
Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress. ( 28270496 )
2017
24
Cutaneous presentation preceding acute monocytic leukemia: A CARE-compliant article. ( 28272239 )
2017
25
Characterization of an acquired jumping translocation involving 3q13.31-qter in a patient with de novo acute monocytic leukemia. ( 28625614 )
2017
26
5‑aza‑2'‑deoxycytidine promotes migration of acute monocytic leukemia cells via activation of CCL2‑CCR2‑ERK signaling pathway. ( 28627644 )
2017
27
Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy. ( 28634616 )
2017
28
Upregulation of long non-coding RNA MALAT-1 confers poor prognosis and influences cell proliferation and apoptosis in acute monocytic leukemia. ( 28713913 )
2017
29
Duplication of subtelomeric regions in an adult with acute monocytic leukemia with an acquired jumping translocation involving 3q13.31-qter. ( 28725672 )
2017
30
Cordycepin induces apoptosis of human acute monocytic leukemia cells via downregulation of the ERK/Akt signaling pathway. ( 28912858 )
2017
31
Spontaneous remission of aleukemic cutaneous myeloid sarcoma followed by crisis of acute monoblastic leukemia. ( 26661142 )
2016
32
Acute monoblastic leukemia with abnormal eosinophils and inversion (16): A rare entity. ( 26960652 )
2016
33
Lineage switch with t(6;11)(q27;q23) from T-cell lymphoblastic lymphoma to acute monoblastic leukemia at relapse. ( 27268298 )
2016
34
Isolated central nervous system primary acute monoblastic leukemia presenting as papilledema. ( 27569601 )
2016
35
Pseudo Chediak-Higashi anomaly in acute monoblastic leukemia. ( 27884836 )
2016
36
Acute monocytic leukemia masked by hemolytic anemia and sclerotic lesions. ( 27572458 )
2016
37
A case of extramedullary involvement of acute monocytic leukemia that presented as obstructive jaundice. ( 26422978 )
2016
38
Polydatin Induces Apoptosis and Inhibits Growth of Acute Monocytic Leukemia Cells. ( 26616494 )
2016
39
Suppression of NRF2-ARE activity sensitizes chemotherapeutic agent-induced cytotoxicity in human acute monocytic leukemia cells. ( 26708503 )
2016
40
Histiocytic differentiation in acute monocytic leukemia. ( 26771450 )
2016
41
Knockdown of p54nrb inhibits migration, invasion and TNF-α release of human acute monocytic leukemia THP1 cells. ( 27108701 )
2016
42
The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia. ( 27408351 )
2016
43
Hypoxia inducible factor-1α regulates a pro-invasive phenotype in acute monocytic leukemia. ( 27447550 )
2016
44
Acute Monocytic Leukemia Masquerading Behçet's Disease-Like Illness at Onset in an Elderly Female. ( 27610252 )
2016
45
Leukemia cutis preceding bone marrow relapse in acute monocytic leukemia. ( 27643547 )
2016
46
Spurious Thrombocytosis Caused by Tumor Cell Lysis in a Patient with Acute Monocytic Leukemia. ( 28164618 )
2016
47
Infantile Acute Monoblastic Leukemia with MLL Gene Rearrangements. ( 25548462 )
2015
48
Transfusion medicine illustrated. Blast cell fragments mimic platelets in acute monoblastic leukemia. ( 26074175 )
2015
49
Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah's Witness with acute monocytic leukemia. ( 25984306 )
2015
50
Histiocytic sarcoma combined with acute monocytic leukemia: a case report. ( 26187047 )
2015
Sources

Variations for Acute Monoblastic Leukemia

About this section

ClinVar genetic disease variations for Acute Monoblastic Leukemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SOS1 NM_005633.3(SOS1): c.2371C> A (p.Leu791Ile) single nucleotide variant Benign rs142004123 GRCh37 Chromosome 2, 39239286: 39239286
2 SOS1 NM_005633.3(SOS1): c.2371C> A (p.Leu791Ile) single nucleotide variant Benign rs142004123 GRCh38 Chromosome 2, 39012145: 39012145
3 STK11 NM_000455.4(STK11): c.970C> G (p.Pro324Ala) single nucleotide variant Conflicting interpretations of pathogenicity rs549474196 GRCh38 Chromosome 19, 1223034: 1223034
4 STK11 NM_000455.4(STK11): c.970C> G (p.Pro324Ala) single nucleotide variant Conflicting interpretations of pathogenicity rs549474196 GRCh37 Chromosome 19, 1223033: 1223033
5 NF1 NM_001042492.2(NF1): c.1588G> A (p.Val530Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs145191978 GRCh37 Chromosome 17, 29546083: 29546083
6 NF1 NM_001042492.2(NF1): c.1588G> A (p.Val530Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs145191978 GRCh38 Chromosome 17, 31219065: 31219065
7 NF1 NM_001042492.2(NF1): c.2747A> G (p.Asn916Ser) single nucleotide variant Uncertain significance rs765043916 GRCh37 Chromosome 17, 29556380: 29556380
8 NF1 NM_001042492.2(NF1): c.2747A> G (p.Asn916Ser) single nucleotide variant Uncertain significance rs765043916 GRCh38 Chromosome 17, 31229362: 31229362
9 TSC2 NM_000548.3(TSC2): c.5336A> G (p.Gln1779Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs748947919 GRCh37 Chromosome 16, 2138523: 2138523
10 TSC2 NM_000548.3(TSC2): c.5336A> G (p.Gln1779Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs748947919 GRCh38 Chromosome 16, 2088522: 2088522
Sources

Expression for Acute Monoblastic Leukemia

About this section
Search GEO for disease gene expression data for Acute Monoblastic Leukemia.
Sources

Pathways for Acute Monoblastic Leukemia

About this section

Pathways related to Acute Monoblastic Leukemia according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Pathways in cancer 38
12.61 CXCL8 EPO IL6 IL7
2
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.2 CSF2 EPO IL6 IL7
3
Transcriptional misregulation in cancer 38
11.94 CSF2 CXCL8 IL6 KMT2A
4
Amoebiasis 38
11.73 CSF2 CXCL8 IL6
5
Cytokine production by Th17 cells in CF (Mouse model) 23
Show member pathways
 11.7 CSF2 CXCL8 IL6
6
Rheumatoid arthritis 38
11.68 CSF2 CXCL8 IL6
7
Salmonella infection (KEGG) 38
11.63 CSF2 CXCL8 IL6
8
Glucocorticoid receptor regulatory network 1
11.6 CSF2 CXCL8 IL6
9
Senescence and Autophagy in Cancer 1
11.48 CD44 CXCL8 IL6 KMT2A
10
Lung fibrosis 1
11.47 CSF2 CXCL8 IL6
11
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.45 CSF2 CXCL8 IL6
12
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.42 CD44 CSF2 EPO IL6 IL7
13
Hepatitis C and Hepatocellular Carcinoma 1
11.34 CD44 CXCL8 IL6
14
Interleukin-10 signaling 67
11.3 CSF2 CXCL8 IL6
15
Hematopoietic Stem Cell Differentiation 1
11.18 CSF2 EPO IL6
16
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.14 CXCL8 IL6
17
Syndecan-2-mediated signaling events 1
11.12 CSF2 CXCL8
18
Development and heterogeneity of the ILC family 1
11.1 IL6 IL7
19
Hematopoietic cell lineage 38
11.01 CD44 CSF2 EPO IL6 IL7
20
G-protein signaling_RhoB regulation pathway 23
10.94 CSF2 CXCL8 IL6 IL7
21
Cytokines and Inflammatory Response 1
10.9 CSF2 IL6 IL7
22
Overview of nanoparticle effects 1
10.85 CXCL8 IL6
23
G-protein signaling_Rap2B regulation pathway 23
10.81 CSF2 CXCL8 IL6 IL7
Sources

GO Terms for Acute Monoblastic Leukemia

About this section

Biological processes related to Acute Monoblastic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.73 CSF2 EPO IL6 IL7
2 immune response GO:0006955 9.67 CSF2 CXCL8 IL6 IL7
3 cellular response to lipopolysaccharide GO:0071222 9.5 CSF2 CXCL8 IL6
4 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.46 CSF2 IL7
5 cytokine-mediated signaling pathway GO:0019221 9.46 CSF2 CXCL8 IL6 IL7
6 cellular response to fibroblast growth factor stimulus GO:0044344 9.4 CD44 CXCL8
7 positive regulation of chemokine production GO:0032722 9.26 IL6 IL7
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.13 CSF2 EPO IL6
9 regulation of signaling receptor activity GO:0010469 9.02 CSF2 CXCL8 EPO IL6 IL7

Molecular functions related to Acute Monoblastic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.13 CSF2 IL6 IL7
2 cytokine activity GO:0005125 9.02 CSF2 CXCL8 EPO IL6 IL7
Sources

Sources for Acute Monoblastic Leukemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....